Truist Financial Forecasts Strong Price Appreciation for Lantheus (NASDAQ:LNTH) Stock

Lantheus (NASDAQ:LNTH) had its target price increased by research analysts at Truist Financial from $115.00 to $125.00 in a report released on Thursday, MarketBeat Ratings reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s target price suggests a potential upside of 16.18% from the company’s previous close.

A number of other research firms have also weighed in on LNTH. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. B. Riley Financial raised their price target on shares of Lantheus from $97.00 to $129.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Wall Street Zen lowered Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. The Goldman Sachs Group restated a “neutral” rating and issued a $94.00 target price on shares of Lantheus in a report on Thursday, May 7th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a research report on Monday, June 29th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.43.

Lantheus Stock Up 2.4%

LNTH stock opened at $107.59 on Thursday. The stock’s 50 day simple moving average is $102.40 and its 200 day simple moving average is $84.23. The company has a market cap of $7.00 billion, a P/E ratio of 25.93 and a beta of -0.06. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. Lantheus has a fifty-two week low of $47.25 and a fifty-two week high of $111.86.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. During the same quarter in the previous year, the company posted $1.53 earnings per share. The company’s quarterly revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, research analysts expect that Lantheus will post 4.5 earnings per share for the current fiscal year.

Institutional Trading of Lantheus

Hedge funds have recently made changes to their positions in the company. Western Wealth Management LLC bought a new position in shares of Lantheus during the 1st quarter worth $25,000. Smartleaf Asset Management LLC lifted its holdings in Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares during the last quarter. Parallel Advisors LLC boosted its position in Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares during the period. Osterweis Capital Management Inc. bought a new position in Lantheus during the second quarter worth about $36,000. Finally, Bessemer Group Inc. increased its stake in shares of Lantheus by 221.2% in the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 354 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.